ASH 2024: Cambridge, UK based CellCentric has a unique approach to targeting p300/CBP and thus reducing the activation of oncogenes like IRF4 and MYC in multiple myeloma

CEO Will West describes how the company focuses on inhibiting the bromodomain of these targets with inobrodib, rather than the active sites, and how this is different than the approaches of other companies. He describes CellCentric's phase 2 data at ASH and the next steps for the program.